AXIM Biotechnologies, Inc. (AXIM)

OTCMKTS: AXIM · Delayed Price · USD
0.0290
-0.0006 (-2.03%)
Jan 13, 2023, 3:28 PM EST - Market open
Market Cap 5.41M
Revenue (ttm) 6,123
Net Income (ttm) -13.39M
Shares Out 186.44M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 500,490
Open 0.0270
Previous Close 0.0296
Day's Range 0.0253 - 0.0290
52-Week Range 0.0200 - 0.2800
Beta 1.54
Analysts n/a
Price Target n/a
Earnings Date n/a

About AXIM

AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation. It is also developing rapid q... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 6
Stock Exchange OTCMKTS
Ticker Symbol AXIM
Full Company Profile

Financial Performance

Financial Statements

News

AXIM® Biotechnologies CEO Issues Letter to Shareholders; Reminds of Conference Call

Summary: In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye ...

3 weeks ago - PRNewsWire

AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent

Leading Diagnostic Healthcare Company Announces Development of and Provisional Patent Filing on First-of-Its-Kind Point-of-Care Ophthalmological Diagnostic Solution Enabling Precision Treatment of Com...

1 month ago - GlobeNewsWire

AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM's Eye Diagnostic Solutions

Technology and Benefits Company At Forefront of Leading Ophthalmological Media Outlets' Coverage of Innovative Diagnostic Solutions Technology and Benefits Company At Forefront of Leading Ophthalmolog...

2 months ago - GlobeNewsWire

AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch

Healthcare Solutions Company Receives Initial Order for Ophthalmic Diagnostic Tests and Readers, Marking First Large Revenue Generating Order for Company Healthcare Solutions Company Receives Initial ...

4 months ago - GlobeNewsWire

AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics' Commercial Launch at AAO 2022

Sales of Point-of-Care Diagnostic Tests for Ocular Surface Disease Commence at the American Academy of Ophthalmology Annual Meeting Through Exclusive Partnership Sales of Point-of-Care Diagnostic Test...

4 months ago - GlobeNewsWire

AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions

Under the Agreement the Company will Sell and Distribute Globally AXIM's Readers and Three Novel Proprietary Tests Designed for Diagnosis of Dry Eye Disease Under the Agreement the Company will Sell a...

5 months ago - GlobeNewsWire

AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface ...

6 months ago - GlobeNewsWire

AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface ...

7 months ago - GlobeNewsWire

AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose

SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their pub...

7 months ago - GlobeNewsWire

AXIM Launches New Eye Care Website; Establishes Platform for Commercialization

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface d...

8 months ago - GlobeNewsWire

AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures

SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface di...

9 months ago - GlobeNewsWire

AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc ( OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease...

9 months ago - GlobeNewsWire

AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Dise...

10 months ago - GlobeNewsWire

AXIM Biotechnologies CEO Issues Letter to Shareholders

AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic system

10 months ago - GlobeNewsWire

AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Disease

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease...

11 months ago - GlobeNewsWire

AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease...

1 year ago - GlobeNewsWire

AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch

SAN DIEGO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease ...

1 year ago - GlobeNewsWire

CDC Publishes AXIM® Biotechnologies-Sponsored Study on COVID-19 Neutralizing Antibodies

SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnos...

1 year ago - GlobeNewsWire

AXIM Biotechnologies Applauds FDA's Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests

Company's first rapid test to measure neutralizing antibodies is currently under FDA review Company's first rapid test to measure neutralizing antibodies is currently under FDA review

1 year ago - GlobeNewsWire

AXIM Biotechnologies Partners with Arizona State University to Determine Antibody Levels Against COVID-19

Company develops COVID-19 “Correlate of Protection” research to measure levels of neutralizing antibodies which protect from infection Company develops COVID-19 “Correlate of Protection” research to m...

1 year ago - GlobeNewsWire

AXIM Biotechnologies' Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% Specificity

Publication in the Journal of Clinical Virology Highlights Effectiveness of the Rapid Test To Identifying Immunity Levels of Functional Antibodies, Preventing the Virus from Infecting Cells Publicatio...

1 year ago - GlobeNewsWire

AXIM Biotechnologies Appoints Clinical Research and DED Expert Dr. Michael E. Stern to its Medical Advisory Board

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19...

1 year ago - GlobeNewsWire

AXIM Biotechnologies Appoints Dry Eye Disease Expert and Accomplished Optometrist Dr. Kelly K. Nichols to its Medical Advisory Board

Dr. Nichols Strengthens Board with 25 Years of Optometry and Academic Experience Dr. Nichols Strengthens Board with 25 Years of Optometry and Academic Experience

1 year ago - GlobeNewsWire

AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COV...

1 year ago - GlobeNewsWire

AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory Board

Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board

1 year ago - GlobeNewsWire